Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
- 21 March 2020
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (6), 798-806
- https://doi.org/10.1016/j.annonc.2020.03.287
Abstract
No abstract availableFunding Information
- AstraZeneca
This publication has 21 references indexed in Scilit:
- PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancerAnnals of Oncology, 2017
- Immune Checkpoint Inhibitors in Non-Small Cell Lung CancerThe Oncologist, 2017
- Application of 3-D Urbanization Index to Assess Impact of Urbanization on Air TemperatureScientific Reports, 2016
- The role of PD-L1 in the radiation response and clinical outcome for bladder cancerScientific Reports, 2016
- Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian CancerCancer Research, 2015
- Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert GroupThorax, 2015
- Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal AntibodyCancer Immunology Research, 2015
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1Clinical Cancer Research, 2012
- Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 2008